Ticker Details
Agios Pharmaceuticals, Inc. Agios Pharmaceuticals Inc is a biopharmaceutical company which focuses on developing treatments geared towards cancer and rare genetic disorders of metabolism. It also emphasizes on developing potentially transformative small-molecule medicines.
IPO Date:	July 24, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.98B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.26 | 2.69%
Avg Daily Range (30 D):	$0.89 | 2.49%
Avg Daily Range (90 D):	$0.88 | 2.71%

Institutional Daily Volume
Avg Daily Volume:	.56M
Avg Daily Volume (30 D):	.93M
Avg Daily Volume (90 D):	.91M

Trade Size
Avg Trade Size (Sh.):	73
Avg Trade Size (Sh.) (30 D):	57
Avg Trade Size (Sh.) (90 D):	56

Institutional Trades
Total Institutional Trades:	6,480
Avg Institutional Trade:	$2.39M
Avg Institutional Trade (30 D):	$3.13M
Avg Institutional Trade (90 D):	$3.24M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.35M
Avg Closing Trade (30 D):	$5.58M
Avg Closing Trade (90 D):	$5.96M
Avg Closing Volume:	84.39K

News

Jul 7, 2026 @ 4:32 PM Here's Why Agios Pharmaceuticals Stock Soared Toda... Source: Lee Samaha

Jun 13, 2026 @ 1:00 PM Agios Showcases RISE UP Phase 3 Results at EHA 202... Source: Agios Pharmaceuticals, Inc.

May 29, 2026 @ 11:00 AM Agios Provides Update on Phase 2b Trial of Tebapiv... Source: Na

Apr 29, 2026 @ 10:27 PM Why Agios Pharmaceuticals Stock Zoomed to a 13% Ga... Source: Eric Volkman

Apr 20, 2026 @ 4:19 PM Here's Why Agios Pharmaceuticals Crashed 23% Today... Source: Lee Samaha

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-7.01	$-1.69	$-1.69
Diluted EPS	$-7.01	$-1.69	$-1.69
Revenue	$98.34M	$44.75M	$20.75M
Gross Profit	$90.47M	$41.75M	$19.43M
Net Income / Loss	$-411.29M	$-100.7M	$-99.11M
Operating Income / Loss	$-459.02M	$-110.55M	$-110.03M
Cost of Revenue	$7.87M	$3M	$1.32M
Net Cash Flow	$18.78M	$-13.95M	$24.47M
PE Ratio